Clinical trials
Non-small Cell Carcinoma clinical trials
Below are recruiting non-small cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 517 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT07354061RecruitingPhase 1/Phase 2
Ensartinib plus chemo before surgery for ALK+ lung cancer
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Xi’an, ShanxiAges 18–75 - NCT04147078RecruitingPhase 1
Personalized immune vaccine after surgery for certain cancers
This Phase 1 study tests a personalized vaccine made for you to help your immune system after you’ve had surgery or ablation for certain cancers. It’s mainly done to check safety and see how well the vaccine can work at preventing cancer from coming back.
Chengdu, SichuanAges 18–100 - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06643000Recruiting
High-dose furmonertinib combo for EGFR lung cancer with brain lining spread
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Zhengzhou, HenanAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07339254Recruiting
Survey about immunotherapy for lung cancer patients
This study is a survey to learn about the experiences and feelings of people with non-small cell lung cancer who are taking immunotherapy drugs. The goal is to understand how you're doing on treatment, which can help improve care for others.
Los Angeles, CaliforniaAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07330050RecruitingPhase 2
Combination treatment for advanced lung cancer after immunotherapy failure
This trial tests a combination of WAST Cell therapy and the chemotherapy drug docetaxel for people with advanced non-small cell lung cancer whose cancer progressed after treatment with a PD-1 inhibitor. The goal is to see if this combination can help shrink tumors and extend survival.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07328945Recruiting
Personalized treatment for non-small cell lung cancer using a tumor model
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT07322341RecruitingPhase 2
Study of SX-682 with atezolizumab for advanced lung cancer
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07264816RecruitingPhase 2
Study of BL-M07D1 and Pembrolizumab for HER2+ Lung Cancer
This study tests a new drug combination, BL-M07D1 plus pembrolizumab (an immunotherapy), for people with a certain type of advanced lung cancer that has high levels of HER2 protein. The goal is to see if the combination is safe and effective for people who have not been treated with HER2-targeting drugs before.
Wuhan, HubeiAges 18–75 - NCT07264647RecruitingPhase 2
Chemo-immunotherapy before surgery for stage III lung cancer
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Rome, Roma (RM)Ages 18–99
Hear when a new Non-small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell carcinoma?
- Yes. Clin2 currently lists 517 recruiting non-small cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.